These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1531 related items for PubMed ID: 33079279

  • 1. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S, Kobayashi Y, Furuya Y, Yasuda H, Fukuda C, Tsuda E.
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [Abstract] [Full Text] [Related]

  • 2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [Abstract] [Full Text] [Related]

  • 3. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
    Ozaki Y, Koide M, Furuya Y, Ninomiya T, Yasuda H, Nakamura M, Kobayashi Y, Takahashi N, Yoshinari N, Udagawa N.
    PLoS One; 2017 Sep; 12(9):e0184904. PubMed ID: 28937990
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T.
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [Abstract] [Full Text] [Related]

  • 9. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N, Udagawa N, Suda T.
    Biochem Biophys Res Commun; 1999 Mar 24; 256(3):449-55. PubMed ID: 10080918
    [Abstract] [Full Text] [Related]

  • 10. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.
    Bone; 2011 Dec 24; 49(6):1290-8. PubMed ID: 21925296
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regulatory mechanisms of RANKL presentation to osteoclast precursors.
    Honma M, Ikebuchi Y, Kariya Y, Suzuki H.
    Curr Osteoporos Rep; 2014 Mar 24; 12(1):115-20. PubMed ID: 24477414
    [Abstract] [Full Text] [Related]

  • 13. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY.
    J Bone Miner Res; 2006 Oct 24; 21(10):1648-56. PubMed ID: 16995820
    [Abstract] [Full Text] [Related]

  • 14. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T.
    Endocrinology; 2000 Sep 24; 141(9):3478-84. PubMed ID: 10965921
    [Abstract] [Full Text] [Related]

  • 15. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T, Takato T, Nakamura K, Kawaguchi H.
    J Bone Miner Res; 2001 Nov 24; 16(11):2074-81. PubMed ID: 11697804
    [Abstract] [Full Text] [Related]

  • 16. Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity.
    Li B, Lu D, Chen Y, Zhao M, Zuo L.
    Int J Mol Sci; 2016 Apr 22; 17(4):. PubMed ID: 27110777
    [Abstract] [Full Text] [Related]

  • 17. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T.
    J Bone Miner Res; 2000 Sep 22; 15(9):1766-75. PubMed ID: 10976996
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of IGF-I signaling in regulating osteoclastogenesis.
    Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD.
    J Bone Miner Res; 2006 Sep 22; 21(9):1350-8. PubMed ID: 16939393
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.